Log in

NASDAQ:ELGX - Endologix Stock Price, Forecast & News

$0.74
-0.06 (-7.52 %)
(As of 03/30/2020 01:21 AM ET)
Today's Range
$0.70
Now: $0.74
$0.92
50-Day Range
$0.66
MA: $0.96
$1.45
52-Week Range
$0.60
Now: $0.74
$8.14
Volume331,165 shs
Average Volume278,631 shs
Market Capitalization$14.08 million
P/E RatioN/A
Dividend YieldN/A
Beta-0.29
Endologix, Inc. develops, manufactures, markets, and sells medical devices for the treatment of abdominal aortic aneurysms in the United States and internationally. The company offers minimally-invasive endovascular aneurysm repair (EVAR), including AFX (Anatomical Fixation) endovascular AAA system, which is a minimally invasive delivery system; VELA Proximal Endograft, which is designed for the treatment of proximal aortic neck anatomies with AFX; and the Ovation abdominal stent graft system. It also provides endovascular aneurysm sealing system (EVAS) product that is based on the Nellix EVAS system to seal the aneurysm, and provides blood flow to the legs through two blood lumens. In addition, the company offers proximal aortic extensions and limb extensions, which allow physicians to customize the implant to fit the patient's anatomy; and accessories to facilitate the delivery of its EVAR and EVAS products, including compatible guidewires, inflation devices, and snares. It sells its products through direct sales force, and a network of third party distributors and agents. The company was formerly known as Radiance Medical Systems, Inc. and changed its name to Endologix, Inc. in May 2002. Endologix, Inc. was founded in 1992 and is headquartered in Irvine, California.
Read More
Endologix logo

Industry, Sector and Symbol

Industry Surgical & medical instruments
Sub-IndustryHealth Care Supplies
SectorMedical
Current SymbolNASDAQ:ELGX
CUSIP29266S10
Phone949-595-7200

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$143.37 million
Book Value$3.56 per share

Profitability

Net Income$-64,760,000.00

Miscellaneous

Employees528
Market Cap$14.08 million
Next Earnings Date5/7/2020 (Estimated)
OptionableOptionable

Receive ELGX News and Ratings via Email

Sign-up to receive the latest news and ratings for ELGX and its competitors with MarketBeat's FREE daily newsletter.


Endologix (NASDAQ:ELGX) Frequently Asked Questions

How has Endologix's stock been impacted by COVID-19 (Coronavirus)?

Endologix's stock was trading at $0.94 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization. Since then, ELGX shares have decreased by 21.5% and is now trading at $0.7376. View which stocks have been mosted impacted by Coronavirus.

Do Wall Street analysts recommend investors buy shares of Endologix?

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Endologix in the last year. There are currently 3 hold ratings and 1 buy rating for the stock, resulting in a consensus recommendation of "Hold." View analyst ratings for Endologix.

When is Endologix's next earnings date?

Endologix is scheduled to release its next quarterly earnings announcement on Thursday, May 7th 2020. View our earnings forecast for Endologix.

How were Endologix's earnings last quarter?

Endologix, Inc. (NASDAQ:ELGX) posted its quarterly earnings results on Wednesday, February, 19th. The medical instruments supplier reported ($0.42) EPS for the quarter, topping the Thomson Reuters' consensus estimate of ($0.70) by $0.28. The medical instruments supplier earned $35.75 million during the quarter, compared to analyst estimates of $35.80 million. Endologix had a negative net margin of 45.17% and a negative return on equity of 65.61%. View Endologix's earnings history.

When did Endologix's stock split? How did Endologix's stock split work?

Shares of Endologix reverse split before market open on Wednesday, March 6th 2019. The 1-10 reverse split was announced on Tuesday, March 5th 2019. The number of shares owned by shareholders was adjusted after the market closes on Tuesday, March 5th 2019. An investor that had 100 shares of Endologix stock prior to the reverse split would have 10 shares after the split.

What guidance has Endologix issued on next quarter's earnings?

Endologix updated its FY 2020 After-Hours earnings guidance on Wednesday, February, 19th. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $145 million, compared to the consensus revenue estimate of $150.02 million.

What price target have analysts set for ELGX?

4 brokerages have issued twelve-month price objectives for Endologix's shares. Their forecasts range from $1.00 to $7.00. On average, they anticipate Endologix's share price to reach $4.60 in the next twelve months. This suggests a possible upside of 523.6% from the stock's current price. View analysts' price targets for Endologix.

Has Endologix been receiving favorable news coverage?

News headlines about ELGX stock have been trending somewhat negative this week, InfoTrie Sentiment reports. The research firm rates the sentiment of press coverage by monitoring more than six thousand blog and news sources in real-time. The firm ranks coverage of companies on a scale of negative five to five, with scores closest to five being the most favorable. Endologix earned a news impact score of -1.8 on InfoTrie's scale. They also gave media coverage about the medical instruments supplier a news buzz of 10.0 out of 10, indicating that recent press coverage is extremely likely to have an effect on the stock's share price in the immediate future. View the latest news aboutEndologix.

Are investors shorting Endologix?

Endologix saw a decline in short interest during the month of March. As of March 13th, there was short interest totaling 521,400 shares, a decline of 5.7% from the February 27th total of 553,200 shares. Based on an average daily volume of 255,400 shares, the days-to-cover ratio is presently 2.0 days. Approximately 3.3% of the shares of the company are short sold. View Endologix's Current Options Chain.

Who are some of Endologix's key competitors?

What other stocks do shareholders of Endologix own?

Who are Endologix's key executives?

Endologix's management team includes the following people:
  • Mr. John Onopchenko, CEO & Director (Age 60)
  • Mr. Vaseem Mahboob, Chief Financial Officer (Age 50)
  • Dr. Michael V. Chobotov, Chief Technology Officer (Age 58)
  • Mr. Jeffrey S. Brown, Chief Operations Officer
  • Mr. Jeremy B. Hayden, Gen. Counsel (Age 49)

What is Endologix's stock symbol?

Endologix trades on the NASDAQ under the ticker symbol "ELGX."

Who are Endologix's major shareholders?

Endologix's stock is owned by a number of institutional and retail investors. Top institutional shareholders include ArrowMark Colorado Holdings LLC (18.76%), Renaissance Technologies LLC (4.21%), Oxford Asset Management LLP (1.50%), Jacobs Levy Equity Management Inc. (1.38%), Partner Fund Management L.P. (0.89%) and New York State Common Retirement Fund (0.63%). Company insiders that own Endologix stock include Christopher G Chavez, Gregory D Waller, John Onopchenko, Thomas F Zenty III, Thomas Wilder and Vaseem Mahboob. View institutional ownership trends for Endologix.

Which major investors are selling Endologix stock?

ELGX stock was sold by a variety of institutional investors in the last quarter, including New York State Common Retirement Fund, Partner Fund Management L.P., Oxford Asset Management LLP, Alambic Investment Management L.P., and Spark Investment Management LLC. Company insiders that have sold Endologix company stock in the last year include Gregory D Waller, and Thomas Wilder. View insider buying and selling activity for Endologix.

Which major investors are buying Endologix stock?

ELGX stock was bought by a variety of institutional investors in the last quarter, including Jacobs Levy Equity Management Inc., ArrowMark Colorado Holdings LLC, Renaissance Technologies LLC, and Perkins Capital Management Inc.. Company insiders that have bought Endologix stock in the last two years include John Onopchenko, Thomas F Zenty III, and Vaseem Mahboob. View insider buying and selling activity for Endologix.

How do I buy shares of Endologix?

Shares of ELGX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Endologix's stock price today?

One share of ELGX stock can currently be purchased for approximately $0.74.

How big of a company is Endologix?

Endologix has a market capitalization of $14.08 million and generates $143.37 million in revenue each year. The medical instruments supplier earns $-64,760,000.00 in net income (profit) each year or ($2.19) on an earnings per share basis. Endologix employs 528 workers across the globe. View additional information about Endologix.

What is Endologix's official website?

The official website for Endologix is http://www.endologix.com/.

How can I contact Endologix?

Endologix's mailing address is 2 MUSICK, IRVINE CA, 92618. The medical instruments supplier can be reached via phone at 949-595-7200 or via email at [email protected]


MarketBeat Community Rating for Endologix (NASDAQ ELGX)

Community Ranking:  2.5 out of 5 (star star half star)
Outperform Votes:  470 (Vote Outperform)
Underperform Votes:  475 (Vote Underperform)
Total Votes:  945
MarketBeat's community ratings are surveys of what our community members think about Endologix and other stocks. Vote "Outperform" if you believe ELGX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ELGX will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 3/30/2020 by MarketBeat.com Staff

Featured Article: Death Cross

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel